INTRODUCING
OxyBridge™
When blood is not an option.
It's urgent:
Trauma is the leading cause of death for young adults in both military and civilian populations. Over 30% of trauma patients die from hemorrhagic shock and 50% of these deaths occur during the pre-hospital period.
It’s about time. A hemoglobin-based oxygen carrier has been sought for time-critical trauma victims and pre-transplant donor organ support for decades.
Hemorrhagic Shock
Donor Organ Transplant
OxyBridge™ Benefits
VirTech Bio Strategic Advantages
BIGGER MOLECULES
OxyBridge™ addresses FDA’s HBOC toxicity concern: megapolymer design prevents blood pressure increaseEASE OF MANUFACTURING
No costly factory to be built. Designed for manufacturing by CMO – FUJIFILM Diosynth Biotechnologies – with FDA CMC experienceFIRST INDICATION DEVICE
First indication is pre-transplant organ perfusion – ex vivo device has lower regulatory hurdlesVirTech Bio Management Team
COL(R) Dallas Hack
COL(R) Dallas Hack, MD, MPH
CEO & Director, Medical Affairs
- US Army, Multinational Force Iraq Command Surgeon
- Director, Combat Casualty Care, 2008-2014
- Coordinated $2Billion in R&D funding
Matias Vidal
Matias Vidal
Co-Founder & Executive Chairman
COL(R) Hack served as Senior Medical Advisor to the Principal Assistant, Research and Technology, US Army Medical Research and Materiel Command (USAMRMC) from 2014 to 2015, where he coordinated Brain Health research.
Martha Farmer
Kim Vandegriff
VP R&D
Phil Farabaugh
COO
W. Richard Light
OxyBridge Inventor
Scientific Advisor
Shawn Bengtson
Quality Assurance Advisor
Virginia Rentko
Veterinary Advisor
Jerry Holmberg
Scientific Advisor
OxyBridge™ Funding
The US Department of Defense has made an oxygen-carrying resuscitation solution a top priority to address field emergencies where a blood transfusion is simply not an option. VirTech Bio has been awarded $13.7M in non-dilutive funding. $10M of that from the US Army Medical Research and Development Command (USAMRDC), via the Medical Technology Enterprise Consortium (MTEC), and an additional $1.7M from US Special Operations Command (SOCOM). This non-dilutive funding effectively leverages the $6.7M in equity funding thus far invested. The awarded funds cover most of the R&D, the cost of eGMP manufacture of OxyBridge™, and the planned Phase 1 clinical study. OxyBridge™ is the most advanced human-derived HBOC platform currently in development for hemorraghic shock and donor organ transplantation. The DoD investment has helped establish VirTech Bio as the leader in the field of hemoglobin oxygen carrier solutions. Please contact us for additional information on our next round of funding: info@virtechbio.com
Our Latest Updates
A Successful 2022 for Our Team, and the Advancement of OxyBridge
Dear Friends and Supporters, As we begin the new year, I would like to share the significant progress we have made during 2022.
VirTech Bio presenting at the Florida Venture Summit Dec. 6, 2022
VirTech Bio presenting at the Florida Venture Summit Dec. 6, 2022 MIAMI, FL. COL(R) Dallas Hack, MD, CEO of VirTech Bio, will present the
Startup creates ‘artificial blood’ and receives funding from the Pentagon
Solution is tested to give an organ donated for transplant longer survival and to help victims of accidents
Dr. Dallas Hack Appointed as CEO of VirTech Bio
Dr. Dallas Hack Appointed as CEO of VirTech Bio VirTech Bio, creators of OxyBridge™, the most advanced human-derived Hemoglobin Based Oxygen Carrier (HBOC) platform currently